About
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Current Value
$32.121 Year Return
Current Value
$32.121 Year Return
Key Details
Market Cap
$5.31B
P/E Ratio
14.98
1Y Stock Return
24.00%
1Y Revenue Growth
-6.36%
Dividend Yield
0.00%
Price to Book
3.6
Strategies that include ALKS
Double maintains 4 strategies that include ALKS - Alkermes Plc
Medium risk
$13,000
0.08%
Health Care Sector
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
348
High risk
$9,200
0.43%
US Small Cap
This strategy tracks a market-cap-weighted index of primarily small-cap US stocks, representing a small portion of the total market. This strategy focuses on the growth potential of smaller companies, offering investors targeted exposure to this dynamic segment of the US equity market. With a diversified portfolio of holdings it provides a broad approach to small-cap investing.
Top Sector
Financials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
596
Stock's related to ALKS
The stocks that are correlated to ALKS - Alkermes Plc are GRAL, GPI, PAG, ACAD, PZZA
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
G GRALGRAIL, Inc. | 40.08% | $886.02M | +91.36% | 0.00% |
| 38.11% | $5.20B | +42.90% | 0.53% | |
| 36.98% | $9.98B | -3.82% | 3.18% | |
| 35.83% | $2.77B | -9.77% | 0.00% | |
| 35.59% | $1.37B | -36.03% | 4.47% | |
| 35.47% | $2.16B | -28.21% | 2.94% | |
C CERSCerus Corp. | 35.15% | $260.11M | -25.53% | 0.00% |
| 35.09% | $316.85M | -36.55% | 0.00% | |
| 34.85% | $807.29M | +23.52% | 1.62% | |
| 34.79% | $10.91B | -22.10% | 1.62% | |
| 34.76% | $15.12B | -0.79% | 1.72% | |
| 34.73% | $2.93B | -47.07% | 0.00% | |
S SCLStepan Co. | 34.14% | $1.23B | -38.12% | 3.04% |
| 34.13% | $1.80B | +53.22% | 0.29% | |
| 33.76% | $379.09M | -38.15% | 9.30% | |
I INMDInMode Ltd. | 33.68% | $1.25B | -12.80% | 0.00% |
| 33.68% | $1.86B | -21.48% | 2.01% | |
| 33.66% | $899.58M | -40.14% | 0.00% | |
| 33.43% | $1.18B | +196.27% | 0.00% | |
A AZTAAzenta, Inc. | 33.41% | $1.62B | -39.99% | 0.00% |
ETF's related to ALKS
The ETFs that are correlated to ALKS - Alkermes Plc are FBT, IBB, XPH, PBE, FXH
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 46.02% | $1.08B | 0.56% | |
| 44.11% | $5.61B | 0.45% | |
| 43.88% | $158.14M | 0.35% | |
| 42.95% | $224.98M | 0.58% | |
| 42.08% | $954.59M | 0.62% | |
| 41.01% | $936.86M | 0.75% | |
| 39.76% | $358.88M | 0.35% | |
X XBISPDR Biotech ETF | 39.70% | $4.76B | 0.35% |
| 38.21% | $200.40M | 0.35% | |
| 38.17% | $284.96M | 0.2% | |
| 38.07% | $5.14B | 0.59% | |
| 36.98% | $784.50M | 0.4% | |
| 36.84% | $1.87B | 0.39% | |
| 36.59% | $1.22B | 0.1% | |
| 36.31% | $13.40B | 0.47% | |
| 36.30% | $514.19M | 0.2% | |
| 36.10% | $47.13M | 0.5% | |
| 36.09% | $78.63B | 0.06% | |
| 36.05% | $6.41B | 0.18% | |
| 35.97% | $10.99B | 0.03% | |
News
Yahoo
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Yahoo
The double-blind trial is expected to enrol around 96 IH patients in total.
Yahoo
ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.
Yahoo
Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive daytime sleepiness.
Finnhub
DUBLIN - People living with schizophrenia or bipolar I disorder often face long and complex diagnostic and treatment journeys.Results from a newly completed survey designed to better understand the...
Yahoo
People living with schizophrenia or bipolar I disorder (BDI) often face long and complex diagnostic and treatment journeys. Results from a newly completed survey designed to better understand the perspectives of healthcare providers on patients' treatment experiences and outcomes indicated that providers often prioritize approaches that support long-term symptom control, treatment consistency and quality of life considerations. This research was conducted online in the U.S. in September 2024 by
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds